105161-33-9

Basic information

• Product Name: 3,3-Dimethoxy-2-(hydroxymethylene)propionitrile sodium salt
• Synonyms: 2-HYDROXYMETHYLENE-3,3-DIMETHOXYPROPIONITRILE SODIUM SALT;HM-DMPN SODIUM SALT;HM-DMPN;2-(Dimethoxymethyl)-3-sodiooxyacrylonitrile;Sodium 2-cyano-3,3-dimethoxy-1-propene-1-olate;Sodium 3,3-dimethoxy-2-cyano-1-propene-1-olate;3,3-Dimethoxy-2-(hydroxymethylene)propionitrile sodium salt
• CAS NO: 105161-33-9
• Molecular Formula: C₆H₈NO₃*Na
• Molecular Weight: 165.12
• Mol File: 105161-33-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,3-Dimethoxy-2-(hydroxymethylene)propionitrile sodium salt(CAS DataBase Reference)
• NIST Chemistry Reference: 3,3-Dimethoxy-2-(hydroxymethylene)propionitrile sodium salt(105161-33-9)
• EPA Substance Registry System: 3,3-Dimethoxy-2-(hydroxymethylene)propionitrile sodium salt(105161-33-9)

Safety Data

• Hazardous Substances Data: 105161-33-9(Hazardous Substances Data)

Usage

Description

3,3-Dimethoxy-2-(hydroxymethylene)propionitrile sodium salt is an organic compound that serves as a versatile reactant and reagent in various organic reactions and synthesis processes.

Uses

Used in Organic Synthesis:
3,3-Dimethoxy-2-(hydroxymethylene)propionitrile sodium salt is used as a reactant and reagent for facilitating a wide range of organic reactions and synthesis. Its unique structure allows it to participate in various chemical transformations, making it a valuable component in the development of new organic compounds and materials.

InChI:InChI=1/C6H9NO3.Na/c1-9-6(10-2)5(3-7)4-8;/h4,6,8H,1-2H3;/q;+1

Upstream product

• 107-31-3 Methyl formate 
• 57597-62-3 3,3-dimethoxypropionitrile 
• 109-94-4 formic acid ethyl ester 
• 69194-03-2 3-methoxy-2-propenenitrile 

Downstream Products

• 21344-31-0 5-cyano-thieno<2,3-b>pyridine 
• 116538-95-5 thieno[3,2-b]pyridine-6-carbonitrile 
• 116538-98-8 1-Benzyl-1H-pyrrolo[2,3-b]pyridine-3,5-dicarbonitrile 
• 116538-96-6 3-aminothieno[3,2-b]pyridine-6-carbonitrile 
• 159831-33-1 1-Ethyl-1H-pyrrolo[2,3-b]pyridine-3,5-dicarbonitrile 
• 125189-43-7 (phenyl-2 ethyl)-1 dicyano-3,5 pyrrolo<2,3-b>pyridine 
• 209521-66-4 (Z)-2-Formyl-3-(3-methoxy-phenylamino)-acrylonitrile 
• 857842-95-6 3,5-dicyano-2-mercaptopyridine 
• 5506-97-8 2-methylpyrimidine-5-carbonitrile 
• 1086393-45-4 1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 
• 85386-15-8 2-phenylpyrimidine-5-carbonitrile 
• 101688-01-1 2-(pyridin-3-yl)pyrimidine-5-carbonitrile 

Relevant articles and documents

Facile Synthesis of Annelated NADH Model Precursors

A convenient route to γ-cyano fused pyridine derivatives, which are precursors of NADH models, is described.The method involves the reaction of 3,3-dimethoxy-2-formyl-propionitrile sodium salt (1) with amino derivatives of electron donating heterocyles le

BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.